Literature DB >> 7828282

Cerebrospinal fluid concentrations of carboplatin in a patient without blood-brain barrier disruption.

V Brunner, P Houyau, E Chatelut, H Roché, P Canal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7828282     DOI: 10.1007/BF00689459

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  8 in total

1.  Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors.

Authors:  R Riccardi; A Riccardi; C Di Rocco; G Carelli; R L Tartaglia; A Lasorella; T Servidei; R Mastrangelo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Cerebrospinal fluid circulation and the blood-brain barrier.

Authors:  W R Shapiro
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

3.  Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study.

Authors:  L T Vlasveld; J H Beynen; W Boogerd; W W Ten Bokkel Huinink; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Cerebrospinal fluid-platinum kinetics of cisplatin in man.

Authors:  J P Armand; J P Macquet; A F LeRoy
Journal:  Cancer Treat Rep       Date:  1983-11

Review 5.  Carboplatin: the clinical spectrum to date.

Authors:  R Canetta; M Rozencweig; S K Carter
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

6.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

Authors:  W R Shapiro; D F Young; B M Mehta
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

7.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Authors:  A H Calvert; D R Newell; L A Gumbrell; S O'Reilly; M Burnell; F E Boxall; Z H Siddik; I R Judson; M E Gore; E Wiltshaw
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

  8 in total
  3 in total

Review 1.  Pharmacokinetic considerations in the treatment of CNS tumours.

Authors:  Susannah Motl; Yanli Zhuang; Christopher M Waters; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  RMP-7 : Potential as an Adjuvant to the Drug Treatment of Brain Tumours.

Authors:  A V Boddy; H D Thomas
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

3.  Toxicity and cerebrospinal fluid levels of carboplatin chronically infused into the brainstem of a primate.

Authors:  R J Strege; Y J Liu; A Kiely; R M Johnson; E M Gillis; P Storm; B S Carson; G I Jallo; M Guarnieri
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.